Checkpoint Capital L.P. Pliant Therapeutics, Inc. Transaction History
Checkpoint Capital L.P.
- $202 Billion
- Q3 2024
A detailed history of Checkpoint Capital L.P. transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Checkpoint Capital L.P. holds 380,000 shares of PLRX stock, worth $4.72 Million. This represents 2.11% of its overall portfolio holdings.
Number of Shares
380,000
Previous 232,200
63.65%
Holding current value
$4.72 Million
Previous $2.5 Billion
70.65%
% of portfolio
2.11%
Previous 1.5%
Shares
2 transactions
Others Institutions Holding PLRX
# of Institutions
168Shares Held
63.2MCall Options Held
245KPut Options Held
373K-
Deep Track Capital, LP Greenwich, CT5.97MShares$74.2 Million2.47% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$61.8 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.83MShares$60.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.53MShares$43.8 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA3.2MShares$39.7 Million2.34% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $605M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...